Tectonic Therapeutics at Stifel 2026 Healthcare Conference: 2027 catalyst push

Tectonic Therapeutics (TECX) showcased its busy 2027 clinical pipeline at the Stifel 2026 Healthcare Conference, highlighting two lead programs: TX45, a relaxin analog for pulmonary hypertension and heart failure with preserved ejection fraction, and TX2100, an APJ antagonist antibody for hereditary hemorrhagic telangiectasia (HHT).

CEO Alise Reicin emphasized a "catalyst-rich 2027," with Phase II data for TX45 expected by the end of January 2027, and additional data from the PH-ILD study in the second half of 2027. The company's cash runway extends through the first quarter of 2029, covering several planned studies, and management believes both programs are supported by early safety, target engagement, and mechanistic data.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.